The Principal Scientist, In Vivo Preclinical Development will play a key role in the pre-clinical team generating IND-enabling data for selection of targeted lipid nanoparticle (tLNP) drug development candidates for various indications, including autoimmune disorders. The individual will serve as a lead scientist developing, executing and communicating novel bioanalytical development strategies that achieve project specific and therapeutic modality development goals.

• Designs, optimizes, executes, and troubleshoots in vivo animal studies and bioanalytical endpoints supporting these in vivo studies.
• Develops protein detection assays via multiple means including flow cytometry, ELISA, and derivative technologies.
• Develops robust assays for characterization of immune parameters such as phenotyping and receptor expression, cytokine expression profiling in blood and tissues from preclinical animal studies or in vitro experiments.
• Coordinates with contract research organizations (CROs) and/or collaborative research teams for the purpose of executing bioanalytical assays required for in vivo screening activities.
• Maintains good laboratory practice-like activities including ALCOA+ online laboratory notebooks, instrument and reagent qualification, and documentation.
• Primary author and reviewer of publications, presentations and study reports/regulatory documents.
• Works cross-functionally with other Research, CMC, Clinical and/or Regulatory functions to align the product strategy with program, portfolio, and corporate goals.
• Present data (written and oral) and participate in project team meetings and cross-departmental team meetings.